康希諾生物(06185.HK)與蓋茨基金會簽署重組脊髓灰質炎疫苗項目資助協議
康希諾生物(06185.HK)宣布,與比爾及梅琳達.蓋茨基金會訂立資助協議,基金會將提供合計逾200萬美元,以支持公司的CS-2036項目,即基於類病毒顆粒(VLP)的重組脊髓灰質炎疫苗進行開發,資金將根據其中所述各開發目標及里程碑的達成情況,按相關付款時間表分階段支付。
康希諾生物表示,CS-2036候選疫苗是一種非傳染性VLP脊髓灰質炎疫苗,在生產過程中不依賴活病毒,預期具有良好的安全性和免疫原性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.